conivaptan has been researched along with sulindac in 2 studies
Studies (conivaptan) | Trials (conivaptan) | Recent Studies (post-2010) (conivaptan) | Studies (sulindac) | Trials (sulindac) | Recent Studies (post-2010) (sulindac) |
---|---|---|---|---|---|
188 | 17 | 64 | 1,462 | 202 | 305 |
Protein | Taxonomy | conivaptan (IC50) | sulindac (IC50) |
---|---|---|---|
Aldo-keto reductase family 1 member B10 | Homo sapiens (human) | 2.69 | |
Aldo-keto reductase family 1 member B1 | Homo sapiens (human) | 2.69 | |
Aldo-keto reductase family 1 member B1 | Bos taurus (cattle) | 0.293 | |
Prostaglandin G/H synthase 2 | Homo sapiens (human) | 8.8 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Mowrey, DD; Sun, T; Tang, P; Tillman, TS; Wells, MM; Xu, Y | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for conivaptan and sulindac
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for conivaptan and sulindac
Article | Year |
---|---|
Ensemble-based virtual screening for cannabinoid-like potentiators of the human glycine receptor α1 for the treatment of pain.
Topics: Analgesics, Non-Narcotic; Animals; Binding Sites; Cannabinoids; Drug Evaluation, Preclinical; Female; Lipids; Molecular Dynamics Simulation; Molecular Targeted Therapy; Nuclear Magnetic Resonance, Biomolecular; Oocytes; Pain; Protein Conformation; Protein Structure, Tertiary; Receptors, Glycine; Reproducibility of Results; Xenopus laevis | 2015 |